Compare Summit Therapeutics Inc (SMMT) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Tidewater Inc — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Tidewater Inc trades at $85.42 (market cap $4.21B). The key difference: Summit Therapeutics Inc is far larger — about 3.3× Tidewater Inc's market cap, and Tidewater Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Tidewater Inc for 26 Days on average.
| SMMT | TDW | |
|---|---|---|
Market Cap | $13.71B | $4.21B |
Volume | 6,173,057 | 590,005 |
Sector | Health | Energy |
52-Week High | $26.38 | $100.61 |
52-Week Low | $12.43 | $47.29 |
Typical Hold Time | 16 Days | 26 Days |
Enterprise Value | $13.04B | $4.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Tidewater (TDW) trades at $84.70, up 1.56% today, with a bullish technical signal from moving averages and a consensus analyst price target of $105.50. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though 2026 shows a decline. Recent news includes the completion of the Wilson Sons Ultratug acquisition and significant institutional buying by BlackRock.
The stock offers upside to the price target but faces risks from earnings volatility, as seen in recent quarterly misses, and exposure to energy market cycles. Investor sentiment is mixed with a majority hold rating from analysts, indicating cautious optimism amid operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
